TKT and neoplasm: Gefitinib exerts antitumour activity through inhibition of EGFR-TK (Rusch et al, 1993; Salomon et al, 1995), but its antitumour activity cannot be predicted by EGFR expression in tumours (Bailey et al, 2003).